Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma.

JSON

Nicoś M, Wojas-Krawczyk K, Krawczyk P, Chmielewska I, Wojcik-Superczyńska M, Reszka K, Kieszko R, Góra-Florek A, Dudek M, Świniuch D, Papiewski W, Całka P, Ciesielka M, Ramlau R, Milanowski J

Arch Med Sci 16 (6) 1496-1500 [2019-11-03; online 2019-11-03]

PubMed 33224359

DOI 10.5114/aoms.2019.89217

Crossref 10.5114/aoms.2019.89217

pmc: PMC7667428
pii: 38386